Schrödinger at Morgan Stanley healthcare conference: cloud push gains speed

Schrödinger reported first-half 2024 revenue growth of 19% and Q2 annual contract value growth of 27%, while raising software revenue guidance by $10 million. Hosted software reached 47% of software revenue, ahead of its 75% by 2027 target, and operating expenses declined 6% as the company targets adjusted EBITDA breakeven by 2028. New AI-enabled workflow product Bunsen has generated record customer interest, while the $55 million Tectora spinout shifts development costs off Schrödinger's balance sheet; Novartis portfolio changes could affect Q3 results.

Analysis

SDGR's investable issue is not the reported booking momentum but whether new workflow products convert into recurring, incremental enterprise spend rather than bundled renewals. The hosted mix should improve visibility and reduce quarter-to-quarter revenue volatility, but it also defers recognition relative to legacy licenses; near-term reported growth can therefore lag ACV even if underlying demand is sound. The key re-rating condition over the next 1-3 quarters is evidence that Bunsen and toxicology modules expand average contract value and net retention, not merely customer interest.

The margin story remains structurally constrained: a 2028 EBITDA target leaves multiple years of execution and cash-burn risk, while spinouts exchange direct R&D expense for illiquid minority stakes whose valuation and realization timing are outside SDGR's control. A concentration risk is emerging around large-pharma platform budgets; NVS portfolio changes illustrate that a customer's R&D reprioritization can affect collaboration revenue independent of software utility. BMY, LLY and NVS may benefit operationally if computational workflows lower discovery-cycle labor and attrition, but the dollar impact is immaterial to their consolidated earnings.

Consensus may be underestimating the defensibility created by proprietary physics validation and deployment workflow, while overestimating how quickly that moat becomes earnings. General AI drug-discovery vendors can pressure pricing and marketing narratives without replicating the platform; conversely, hyperscaler-enabled biology models could make software orchestration a commodity. After the sharp share appreciation, SDGR needs Q4 bookings, disclosed Bunsen conversion metrics, and maintained expense discipline to justify further upside rather than simply a continuation of AI enthusiasm.

Key Decisions for Investors

• Maintain a watch-to-buy stance on SDGR rather than chase conference-driven strength; initiate only after the next earnings release demonstrates software growth/ACV durability and no material NVS collaboration reset. Target a 6-12 month position sized as a high-volatility satellite, with thesis invalidated by decelerating ACV or upward operating-expense guidance.
• For existing SDGR longs, use a 3-6 month collar around the next earnings event: retain exposure to Bunsen conversion upside while financing downside protection against delayed revenue recognition, collaboration volatility, or another extension of the profitability timeline.
• Pair long SDGR / short a broad biotech software or early-stage AI-discovery basket only if relative valuation data confirm SDGR is not already carrying a material premium; the intended exposure is to software monetization and workflow adoption, not beta to biotech funding conditions.
• Do not express the thesis through BMY, LLY, or NVS. Their potential productivity gains are too small relative to pipeline, patent-cycle, and therapeutic-area drivers; monitor NVS's portfolio actions instead as a near-term SDGR revenue-risk indicator.